{"product_id":"casi-vrio-analysis","title":"CASI Pharmaceuticals, Inc. (CASI): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking the secrets to CASI Pharmaceuticals, Inc. (CASI)'s market dominance starts here: this VRIO analysis distills exactly which of their resources are truly Valuable, Rare, Inimitable, and Organized for sustained competitive advantage. Don't just wonder about their success - read on to see the precise, actionable insights that define their edge.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCASI Pharmaceuticals, Inc. (CASI) - VRIO Analysis: Exclusive Global Rights to CID-103\n\u003c\/h2\u003e\n\u003cp\u003eYou’re assessing the core value driver for CASI Pharmaceuticals, Inc. (CASI), and it clearly centers on the exclusive global rights to CID-103. This asset is the linchpin of your investment thesis right now, especially given the company’s tight financial runway.\u003c\/p\u003e\n\n\u003ch3 id=\"value\"\u003eValue: Addressing a Critical Unmet Need\u003c\/h3\u003e\n\u003cp\u003eThe value here is immense because CID-103 targets Antibody-Mediated Rejection (AMR) in transplant patients, a condition where there is currently no FDA-approved treatment. Consider this: in the US alone, about 12% of kidney transplant patients face acute or chronic AMR, which translates to over 30,000 people needing a solution. The ongoing Phase 1\/2 study in Immune Thrombocytopenia (ITP) is also progressing, with dosing reaching the 900 mg cohort. If the data presented at ASH 2025 on December 7, 2025, is positive, that value realization accelerates significantly.\u003c\/p\u003e\n\n\u003ch3 id=\"rarity\"\u003eRarity: Worldwide Ownership of a Novel Mechanism\u003c\/h3\u003e\n\u003cp\u003eOwning the worldwide rights to a novel, clinical-stage anti-CD38 monoclonal antibody targeting a unique epitope for AMR is genuinely rare in this space. Most competitors are focused on CD20 or CD19, which don't deplete the persistent plasma cells that drive AMR. This exclusivity means CASI controls the upside for a first-in-class or best-in-class therapy across all major markets, which is a high bar for any competitor to clear.\u003c\/p\u003e\n\n\u003ch3 id=\"imitability\"\u003eImitability: The R\u0026amp;D Moat\u003c\/h3\u003e\n\u003cp\u003eReplicating CID-103 is tough. It’s not just about the target; it’s about the specific molecule, its unique epitope targeting, and the years of pre-clinical and early clinical data already generated. To copy this, another firm would need to spend significant capital and time navigating the same regulatory pathways, including the FDA IND clearance CASI already secured for AMR. Honestly, the sunk cost and time investment create a substantial barrier to imitation.\u003c\/p\u003e\n\n\u003ch3 id=\"organization\"\u003eOrganization: Focused Resource Allocation\u003c\/h3\u003e\n\u003cp\u003eManagement is clearly putting nearly all its chips on this single asset. Here’s the quick math: for the third quarter of 2025, Research and Development (R\u0026amp;D) expenses were $1.4 million, which is stable compared to the prior year's $1.5 million. However, the cash position is tight - cash and cash equivalents stood at only $4.7 million as of September 30, 2025, down from $13.5 million at the end of 2024. What this estimate hides is the burn rate needed to get through the next critical clinical readout. The company raised $5.7 million in Q3 2025 via its ATM facility, showing they are actively managing this cash crunch to keep CID-103 moving. They are organized around this asset, but the financial runway is short.\u003c\/p\u003e\n\n\u003ch3 id=\"competitive-advantage-scoring\"\u003eVRIO Competitive Advantage Scoring Summary\u003c\/h3\u003e\n\u003cp\u003eWe map the dimensions to determine the resulting advantage. This is the core of your strategic view.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eScore\/Implication\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue (V)\u003c\/td\u003e\n\u003ctd\u003eAddresses $0 FDA-approved AMR market need.\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity (R)\u003c\/td\u003e\n\u003ctd\u003eExclusive worldwide rights to a novel anti-CD38.\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability (I)\u003c\/td\u003e\n\u003ctd\u003eHigh R\u0026amp;D cost and time to replicate molecule\/data.\u003c\/td\u003e\n\u003ctd\u003eDifficult\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (O)\u003c\/td\u003e\n\u003ctd\u003eManagement focused, but cash position of $4.7M is stressed.\u003c\/td\u003e\n\u003ctd\u003eOrganized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eSustained Potential\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSustained Advantage\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe current advantage is \u003cstrong\u003eSustained\u003c\/strong\u003e, provided CASI Pharmaceuticals, Inc. can successfully navigate the near-term financial risks and translate the clinical progress into positive data. If onboarding for the AMR study, planned for Q1 2026, takes longer than expected, the cash burn will accelerate the risk of needing dilutive financing before a major value inflection point.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCASI Pharmaceuticals, Inc. (CASI) - VRIO Analysis: CID-103 Clinical Development Momentum\n\u003c\/h2\u003e\n\u003cp\u003e\nCID-103, a fully human IgG1 anti-CD38 monoclonal antibody, represents the cornerstone of CASI's current strategic focus on organ transplant rejection and autoimmune diseases.\n\u003c\/p\u003e\n\n\u003ch5\u003eValue\u003c\/h5\u003e\n\u003cp\u003e\n\u003cstrong\u003eValue\u003c\/strong\u003e: High; the asset is actively progressing, with the ITP study dosing at the 900 mg level and securing FDA IND clearance for the U.S. AMR Phase 1 study.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePhase 1\/2 dose-escalation study of CID-103 in chronic immune thrombocytopenia (ITP) is enrolling and dosing at the highest dose cohort of 900 mg target dose.\u003c\/li\u003e\n\u003cli\u003eFDA clearance of IND application for CID-103 in active and chronic active renal allograft antibody-mediated rejection (AMR) has been secured.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch5\u003eRarity\u003c\/h5\u003e\n\u003cp\u003e\n\u003cstrong\u003eRarity\u003c\/strong\u003e: Moderate; while trials are common, achieving clean IND clearance for a novel indication like AMR is a significant, non-trivial milestone.\n\u003c\/p\u003e\n\n\u003ch5\u003eImitability\u003c\/h5\u003e\n\u003cp\u003e\n\u003cstrong\u003eImitability\u003c\/strong\u003e: Difficult; the specific clinical data generated is unique to CASI’s execution.\n\u003c\/p\u003e\n\n\u003ch5\u003eOrganization\u003c\/h5\u003e\n\u003cp\u003e\n\u003cstrong\u003eOrganization\u003c\/strong\u003e: High; R\u0026amp;D expenses in Q2 2025 were up 31% primarily to support this focused development.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expense Change YoY\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUp 31%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025 vs Q2 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eITP Study Dose Level Reached\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e900 mg\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePhase 1\/2 Dose Escalation (Cohort 5 Target)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Shares Outstanding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e20,548,273\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch5\u003eCompetitive Advantage\u003c\/h5\u003e\n\u003cp\u003e\n\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary (until pivotal data is generated).\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCASI Pharmaceuticals, Inc. (CASI) - VRIO Analysis: Strategic Focus on Non-Asian Markets\n\u003c\/h2\u003e\n\u003cp\u003eThe strategic focus shift is underpinned by a significant transaction aimed at resource concentration on non-Asian, primarily U.S., development pathways for core assets.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eDate\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAggregate Purchase Price (Divestiture)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMay 12, 2025 Agreement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndebtedness Assumed (Divestiture)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$20.0 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eMay 12, 2025 Agreement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMarch 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQuarter ended September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Net Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQuarter ended September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eATM Raise (3Q 2025)\u003c\/td\u003e\n\u003ctd\u003e~\u003cstrong\u003e$5.7M\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e3Q 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eStrategic Focus on Non-Asian Markets\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: High; the May 12, 2025 divestiture of Chinese assets for an aggregate purchase price of \u003cstrong\u003e$20.0 million\u003c\/strong\u003e (including assumption of up to \u003cstrong\u003e$20.0 million\u003c\/strong\u003e of indebtedness) sharpens focus, which is critical given the low cash balance of \u003cstrong\u003e$10.9 million\u003c\/strong\u003e as of \u003cstrong\u003eMarch 31, 2025\u003c\/strong\u003e, which further decreased to \u003cstrong\u003e$4.7 million\u003c\/strong\u003e by \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Low; asset sales happen, but this specific, large-scale divestiture to streamline operations is unique to CASI’s recent history.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Easy; competitors can sell non-core assets if they choose to.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: High; the management team successfully executed this complex strategic pivot.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary (value is realized only if the focused U.S.\/Global pipeline succeeds).\u003c\/p\u003e\n\u003cp\u003eThe retained pipeline rights for non-Asian markets center on key assets:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCID-103 (in Japan and non-Asian regions)\u003c\/li\u003e\n\u003cli\u003eEVOMELA®\u003c\/li\u003e\n\u003cli\u003eFOLOTYN®\u003c\/li\u003e\n\u003cli\u003eCNCT19\u003c\/li\u003e\n\u003cli\u003eCB-5339\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eKey development milestones for the focused asset, CID-103, as of the Third Quarter 2025 report:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCID-103 for Antibody-Mediated Rejection (AMR) for Renal Allografts: FDA clearance of IND application; Phase 1 study in U.S. preparation ongoing.\u003c\/li\u003e\n\u003cli\u003eCID-103 for Immune Thrombocytopenia (ITP): Phase 1 dose-escalation study enrolling and dosing at highest dose of \u003cstrong\u003e900 mg\u003c\/strong\u003e; Poster presentation of results at ASH 2025 on \u003cstrong\u003eDecember 7, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCASI Pharmaceuticals, Inc. (CASI) - VRIO Analysis: U.S. Regulatory Pathway Navigation\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e High; securing the FDA IND clearance for the CID-103 AMR program shows the team can successfully navigate U.S. regulatory hurdles. The FDA clearance for the CID-103 Investigational New Drug (IND) application for renal allograft Antibody-Mediated Rejection (AMR) was announced on \u003cstrong\u003eAugust 4, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; having the specific expertise to resolve regulatory issues and gain clearance for a novel mechanism is a specialized skill. The team previously secured FDA IND clearance for CID-103 in Immune Thrombocytopenic Purpura (ITP) in May 2024.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; requires a dedicated, experienced regulatory affairs team. The AMR IND clearance followed a clinical hold notification received on \u003cstrong\u003eDecember 26, 2024\u003c\/strong\u003e, indicating successful resolution of a significant regulatory setback.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; this capability directly resulted in the planned \u003cstrong\u003eQ1 2026\u003c\/strong\u003e U.S. AMR study initiation.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary (must be continually proven with each new submission).\u003c\/p\u003e\n\n\u003cp\u003eThe successful navigation of the U.S. regulatory environment for CID-103 is evidenced by key clinical and financial data points:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eRegulatory Milestone\u003c\/th\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eDate\/Status\u003c\/th\u003e\n\u003cth\u003eRelated Financial Context (3Q 2025)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIND Clearance Received\u003c\/td\u003e\n\u003ctd\u003eRenal Allograft AMR\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eAugust 4, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D Expenses: \u003cstrong\u003e$1.4 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIND Clearance Received\u003c\/td\u003e\n\u003ctd\u003eImmune Thrombocytopenia (ITP)\u003c\/td\u003e\n\u003ctd\u003eMay 2024\u003c\/td\u003e\n\u003ctd\u003ePhase 1 ITP Dosing Reached: \u003cstrong\u003e900 mg\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Hold Resolution\u003c\/td\u003e\n\u003ctd\u003eRenal Allograft AMR\u003c\/td\u003e\n\u003ctd\u003eCleared by August 2025\u003c\/td\u003e\n\u003ctd\u003ePlanned U.S. AMR Study Initiation Target: \u003cstrong\u003eQ1 2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFinancial metrics as of the \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e reporting period illustrate the resource base supporting these regulatory efforts:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eRevenue for 3Q 2025: \u003cstrong\u003e$3.1 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eNet Loss for 3Q 2025: \u003cstrong\u003e$10.9 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCash and Cash Equivalents: \u003cstrong\u003e$4.7 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCapital Raised via ATM in 3Q 2025: $\\sim$\u003cstrong\u003e$5.7 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eTotal Shares Outstanding: \u003cstrong\u003e20,548,273\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eGeneral and Administrative Expenses (3Q 2025): \u003cstrong\u003e$4.9 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCASI Pharmaceuticals, Inc. (CASI) - VRIO Analysis: EVOMELA®\/Legacy Product Revenue Stream\n\u003c\/h2\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eModerate; this stream provided \u003cstrong\u003e$6.2 million\u003c\/strong\u003e in revenue in Q1 2025, acting as a crucial, albeit shrinking, cash buffer.\u003c\/p\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eLow; these are established products, though the Q3 2025 revenue dropped \u003cstrong\u003e60%\u003c\/strong\u003e due to return estimates.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eEasy; competitors can market similar, established products, evidenced by the launch of an undifferentiated generic formulation of melphalan for injection product by a Chinese domestic manufacture in 2023.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eModerate; the company is clearly de-emphasizing this, as evidenced by the divestiture agreement announced on May 12, 2025, with a targeted completion of the China business divestiture in Q2 2026, while retaining EVOMELA® rights.\u003c\/p\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eNone (Competitive Parity).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEVOMELA®\/Legacy Product Revenue and Financial Context\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ1 2025\u003c\/th\u003e\n\u003cth\u003eQ3 2025\u003c\/th\u003e\n\u003cth\u003eQ3 2024\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (USD)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$7.8 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Change YoY\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e+82%\u003c\/strong\u003e vs prior year\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-60%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eSupporting Financial and Legal Context:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe \u003cstrong\u003e60%\u003c\/strong\u003e year-over-year revenue decrease in Q3 2025 was mainly attributable to the Company's estimation of goods return for EVOMELA® following a modified distribution agreement in June 2025.\u003c\/li\u003e\n\u003cli\u003eGeneral and administrative expenses in Q1 2025 were \u003cstrong\u003e$7.7 million\u003c\/strong\u003e, a \u003cstrong\u003e60%\u003c\/strong\u003e increase from the prior year, mainly due to legal fees related to the dispute with Acrotech.\u003c\/li\u003e\n\u003cli\u003eThe Company expects to retain the rights related to EVOMELA® after the closing of the China asset divestiture.\u003c\/li\u003e\n\u003cli\u003eAs of September 30, 2025, cash and cash equivalents were \u003cstrong\u003e$4.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCASI Pharmaceuticals, Inc. (CASI) - VRIO Analysis: Cash Management and Capital Access\n\u003c\/h2\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eModerate; the ability to raise capital via the At-The-Market (ATM) facility, securing about \u003cstrong\u003e$5.7 million\u003c\/strong\u003e (after commissions) in 3Q 2025, is vital when cash is tight.\u003c\/p\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eLow; most public companies have access to ATM facilities.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eEasy; this is a standard financing tool.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eHigh; management successfully accessed capital to bridge the gap, despite the low ending cash balance of \u003cstrong\u003e$4.7 million\u003c\/strong\u003e on September 30, 2025.\u003c\/p\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eTemporary (liquidity is constantly threatened by the \u003cstrong\u003e$10.9 million\u003c\/strong\u003e quarterly net loss).\u003c\/p\u003e\n\u003cp\u003eThe following table summarizes key financial figures for the period ending September 30, 2025:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ3 2025 Amount\u003c\/th\u003e\n\u003cth\u003eComparison Point\u003c\/th\u003e\n\u003cth\u003eReference Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss (Q3)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompared to $8.4 million in the same period last year\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompared to $13.5 million\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapital Raised via ATM\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~$5.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDuring 3Q 2025\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Shares Outstanding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e20,548,273\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of period end\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eAdditional details regarding the cash position and capital activity:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash and cash equivalents as of December 31, 2024, were \u003cstrong\u003e$13.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe net loss for the third quarter of 2025 was \u003cstrong\u003e$10.88 million\u003c\/strong\u003e, compared to $8.4 million a year ago.\u003c\/li\u003e\n\u003cli\u003eRevenues for the third quarter of 2025 were \u003cstrong\u003e$3.1 million\u003c\/strong\u003e, a 60% decrease year-over-year.\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses for the third quarter of 2025 were \u003cstrong\u003e$1.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGeneral and administrative expenses for the third quarter of 2025 were \u003cstrong\u003e$4.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCASI Pharmaceuticals, Inc. (CASI) - VRIO Analysis: CID-103 Delivery Technology Assessment\n\u003c\/h2\u003e\n\n\u003cp\u003eThe assessment of the subcutaneous (SQ) delivery technology for CID-103 is framed against the backdrop of the drug's current clinical progression and financial standing.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: High potential\u003c\/strong\u003e; actively assessing technologies for a subcutaneous (SQ) delivery formulation could significantly improve patient compliance and market uptake for CID-103. The need for non-Intravenous (IV) administration is noted, particularly for kidney transplant patients whose venous access is often compromised following years of dialysis. Preclinical data for CID-103 suggests strong antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) activity while reducing complement-dependent cytotoxicity (CDC) activity.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: Moderate\u003c\/strong\u003e; many firms explore delivery improvements, but securing the right technology for a complex mAb is not guaranteed. CASI is 'assessing multiple technologies for development of a stable, high concentration protein solution for subcutaneous formulation.'\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: Moderate\u003c\/strong\u003e; depends on proprietary partnerships or internal formulation science.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: Moderate\u003c\/strong\u003e; it’s in the assessment stage, showing forward-thinking but not yet a deployed asset. The company's focus on CID-103 is evidenced by Research and Development expenses for the second quarter of 2025 being $1.7 million, up 31% from $1.3 million in the same period last year. As of June 30, 2025, cash and cash equivalents stood at $6.7 million.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary\u003c\/strong\u003e (until a superior formulation is locked in).\u003c\/p\u003e\n\n\u003cp\u003eKey quantitative data points related to the CID-103 program supporting this assessment include:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCID-103 ITP Phase 1 Dose Cohorts\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e30 mg, 150 mg, 300 mg, 600 mg, 900 mg\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCID-103 ITP Study Cohorts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCID-103 ITP Priming Dose\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e30 mg or 150 mg\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCID-103 ITP Study Priming Dose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAMR Phase 1 Study Initiation Plan\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eQ3 2025\u003c\/strong\u003e or \u003cstrong\u003eQ1 2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePlanned initiation for renal allograft AMR study\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 2025 R\u0026amp;D Expense\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSupporting CID-103 advancement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash as of June 30, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAvailable capital\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe development status of CID-103, which is a fully human IgG1 anti-CD38 monoclonal antibody targeting a unique epitope, is:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePhase 1\/2 dose-escalation study in chronic immune thrombocytopenic purpura (ITP) is enrolling and dosing.\u003c\/li\u003e\n\u003cli\u003eFDA clearance of IND application for active and chronic active renal allograft antibody-mediated rejection (AMR); Phase 1 study planned to initiate in the third quarter of 2025 or first quarter of 2026.\u003c\/li\u003e\n\u003cli\u003eCID-103 has exclusive global rights for CASI.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCASI Pharmaceuticals, Inc. (CASI) - VRIO Analysis: Management Team's Strategic Acumen\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eManagement Team's Strategic Acumen\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: High\u003c\/strong\u003e; the leadership demonstrated the ability to make tough, value-accretive decisions, like the China divestiture, to focus on the core pipeline.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eDecision\/Metric\u003c\/th\u003e\n\u003cth\u003eFinancial\/Statistical Data\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina Divestiture Transaction Value\u003c\/td\u003e\n\u003ctd\u003eAggregate purchase price of \u003cstrong\u003e$20.0 million\u003c\/strong\u003e, including assumption of up to \u003cstrong\u003e$20.0 million\u003c\/strong\u003e of indebtedness.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategic Focus Pipeline\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eCID-103\u003c\/strong\u003e advancement for organ transplant rejection and autoimmune diseases.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 2025 Revenue\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$6.2 million\u003c\/strong\u003e, an \u003cstrong\u003e82%\u003c\/strong\u003e increase year-over-year from $3.4 million.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 2025 Revenue\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$4.2 million\u003c\/strong\u003e, a \u003cstrong\u003e5%\u003c\/strong\u003e increase year-over-year from $4.0 million.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Revenue\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$3.1 million\u003c\/strong\u003e, a \u003cstrong\u003e60%\u003c\/strong\u003e decrease year-over-year from $7.8 million.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position (Mar 31, 2025)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$10.9 million\u003c\/strong\u003e, a \u003cstrong\u003e19%\u003c\/strong\u003e decrease from $13.5 million (Dec 31, 2024).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position (Sep 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$4.7 million\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 2025 R\u0026amp;D Expense\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$1.9 million\u003c\/strong\u003e, down \u003cstrong\u003e24%\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCID-103 Regulatory Status\u003c\/td\u003e\n\u003ctd\u003eReceived FDA clearance for Phase 1 study in renal allograft antibody-mediated rejection (AMR).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: Moderate\u003c\/strong\u003e; the quality of executive decision-making under financial duress is not easily replicated.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet Loss Q1 2025: \u003cstrong\u003e$10.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Loss Q2 2025: \u003cstrong\u003e$13.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Loss Q3 2025: \u003cstrong\u003e$10.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNasdaq Non-Compliance Date (MVLS below \u003cstrong\u003e$35 million\u003c\/strong\u003e): May 5, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: Difficult\u003c\/strong\u003e; relies on the specific experience and alignment of the current CEO and Board.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eLeadership Role\u003c\/th\u003e\n\u003cth\u003eIndividual\u003c\/th\u003e\n\u003cth\u003eExperience\/Tenure Data\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew CEO (Appointed Jul 21, 2025)\u003c\/td\u003e\n\u003ctd\u003eDavid Cory\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e30 years\u003c\/strong\u003e of operational experience; over \u003cstrong\u003e$1B+\u003c\/strong\u003e raised.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExecutive Chairman (Former CEO)\u003c\/td\u003e\n\u003ctd\u003eDr. Wei-Wu He\u003c\/td\u003e\n\u003ctd\u003eRemained on the Board after CEO transition.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-Executive Chairman (Appointed Nov 17, 2025)\u003c\/td\u003e\n\u003ctd\u003eJames Huang\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e35 years\u003c\/strong\u003e of experience building and investing in biopharma companies.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManagement Average Tenure\u003c\/td\u003e\n\u003ctd\u003eExecutive Team\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2.4 years\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBoard Average Tenure\u003c\/td\u003e\n\u003ctd\u003eBoard Members\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e10.2 years\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: High\u003c\/strong\u003e; the strategic pivot was announced and executed in 2025.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eChina Divestiture Announcement Date: May 12, 2025.\u003c\/li\u003e\n\u003cli\u003eNew CEO Appointment Date: July 21, 2025.\u003c\/li\u003e\n\u003cli\u003eTargeted Completion of China Divestiture: Q2 2026.\u003c\/li\u003e\n\u003cli\u003eCapital Raised in Q3 2025 via ATM: Approx. \u003cstrong\u003e$5.7 million\u003c\/strong\u003e (after commissions).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary\u003c\/strong\u003e (depends on continued successful execution).\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCASI Pharmaceuticals, Inc. (CASI) - VRIO Analysis: U.S. Commercial\/Marketing Infrastructure\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Moderate; this capability drove the \u003cstrong\u003e82%\u003c\/strong\u003e year-over-year revenue increase in \u003cstrong\u003eQ1 2025\u003c\/strong\u003e, reaching \u003cstrong\u003e$6.2 million\u003c\/strong\u003e, showing some market penetration ability.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; standard for a company with commercial products, though facing local competition in certain areas, evidenced by Selling and marketing expenses for the second quarter of 2025 being \u003cstrong\u003e$5.0 million\u003c\/strong\u003e, up \u003cstrong\u003e14%\u003c\/strong\u003e from \u003cstrong\u003e$4.4 million\u003c\/strong\u003e in the same period last year due to intensified competition from local melphalan generic products.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Easy; sales and marketing teams can be hired by competitors.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate; the \u003cstrong\u003eQ3 2025\u003c\/strong\u003e selling and marketing spend was \u003cstrong\u003e$4.6 million\u003c\/strong\u003e, a \u003cstrong\u003e6%\u003c\/strong\u003e decrease compared to \u003cstrong\u003e$4.9 million\u003c\/strong\u003e in the same period last year, indicating ongoing commitment.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary (erodes quickly against local generic competition).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eKey Financial Metrics Related to Commercial Operations:\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ1 2025\u003c\/th\u003e\n\u003cth\u003eQ3 2025\u003c\/th\u003e\n\u003cth\u003eYoY Change (Q1 2025 vs Q1 2024)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+82%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSelling \u0026amp; Marketing Expense\u003c\/td\u003e\n\u003ctd\u003eNot explicitly stated for Q1\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e-6%\u003c\/strong\u003e (Q3 2025 vs Q3 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e+14%\u003c\/strong\u003e (Q1 2025 vs Q1 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents (Period End)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$10.9 million\u003c\/strong\u003e (as of March 31, 2025)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$4.7 million\u003c\/strong\u003e (as of September 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e-19%\u003c\/strong\u003e (Q1 2025 vs Dec 31, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eSupporting Organizational and Financial Details:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRevenues for the first quarter of 2025 were \u003cstrong\u003e$6.2 million\u003c\/strong\u003e, compared to \u003cstrong\u003e$3.4 million\u003c\/strong\u003e in the same period last year.\u003c\/li\u003e\n\u003cli\u003eGeneral and administrative expenses for the first quarter of 2025 were \u003cstrong\u003e$7.7 million\u003c\/strong\u003e, representing a \u003cstrong\u003e60%\u003c\/strong\u003e increase from \u003cstrong\u003e$4.8 million\u003c\/strong\u003e in the same period last year, mainly attributable to legal fees.\u003c\/li\u003e\n\u003cli\u003eCumulative revenue for the first three quarters of 2025 was \u003cstrong\u003e$13.49 million\u003c\/strong\u003e, down \u003cstrong\u003e11.14%\u003c\/strong\u003e from \u003cstrong\u003e$15.18 million\u003c\/strong\u003e year over year.\u003c\/li\u003e\n\u003cli\u003eCumulative net loss for the first three quarters of 2025 was \u003cstrong\u003e$35.02 million\u003c\/strong\u003e, expanding \u003cstrong\u003e40.69%\u003c\/strong\u003e from \u003cstrong\u003e$-24.89 million\u003c\/strong\u003e year over year.\u003c\/li\u003e\n\u003cli\u003eAs of September 30, 2025, CASI total shares outstanding was \u003cstrong\u003e20,548,273\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516131926165,"sku":"casi-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/casi-vrio-analysis.png?v=1740157814","url":"https:\/\/dcf-model.com\/es\/products\/casi-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}